It’s a good day for United Therapeutics Corp.
The Silver Spring biotech announced Monday its pulmonary arterial hypertension treatment, Tyvaso, essentially passed its clinical tests among patients with interstitial lung disease — a bright spot after the company faced back-to-back failed late-stage trials in both a cancer therapy and a different PAH product in the last year-plus.
The phase 3 trial, per a preliminary analysis, demonstrated that 16 weeks of treatment with Tyvaso was effective in increasing the distance, by 21 meters, that patients could walk in six minutes when compared with a placebo. The study also found the drug successfully met other, secondary endpoints, including its safety measures and the length of time before a patient’s condition starts to worsen.
The news sent the company’s stock rising nearly 7% in Monday afternoon trading to $114.41 per share by about 1:45 p.m.
Tyvaso could fill a major unmet medical need — there are currently no approved therapies…Read the full story from the Washington Business Journal.